The role of positron emission tomography (PET) during the past decade has evolved rapidly
from a pure research tool to a methodology of enormous clinical potential. Perhaps the most …

Background: Sarcomas represent a significant diagnostic and therapeutic challenge that
requires techniques to provide better assessment of the disease than provided by traditional …

PURPOSE: To determine whether treatment-induced pathologic necrosis correlates with
local recurrence and overall survival in patients who receive neoadjuvant therapy for high …

Sarcomas—like leukemias, which are also mesodermal malignancies—carry biological
significance disproportionate to their clinical frequency. Identification of mutations and …

Positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG) was performed
in non-Hodgkin's lymphoma (NHL), which is known to be highly responsive to …

PET using 18F-FDG is increasingly used for the diagnosis and grading of tumors. Several
studies have been performed that evaluate the diagnostic and grading performance of 18F …

Less than 50%, of newly diagnosed patients with aggressive histology Non-Hodgkin's
Lymphoma (NHL) are cured with standard treatment. The ability to accurately monitor …

Purpose: Change in tumor size as classified by Response Evaluation Criteria in Solid
Tumors poorly correlates with histopathologic response to neoadjuvant therapy in patients …

The use of FDG-PET imaging in tumour detection is now well established. Many studies
have suggested that changes in the uptake of FDG predict tumour response to therapy and …

BACKGROUND Response to neoadjuvant chemotherapy is a significant prognostic factor
for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). Conventional …